

Pier Luigi Zinzani

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3406813/pier-luigi-zinzani-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

676
papers

30,982
citations

85
h-index

160
g-index

702
ext. papers

36,043
ext. citations

4.9
avg, IF

6.54
L-index

#	Paper	IF	Citations
676	CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MINT) Group. <i>Lancet Oncology, The</i> , 2006 , 7, 379-91	21.7	1567
675	Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2010 , 376, 1164-74	40	1471
674	Follicular lymphoma international prognostic index. <i>Blood</i> , 2004 , 104, 1258-65	2.2	1348
673	PI3K inhibition by idelalisib in patients with relapsed indolent lymphoma. <i>New England Journal of Medicine</i> , 2014 , 370, 1008-18	59.2	784
672	Nivolumab for classical Hodgkin lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1283-94	21.7	643
671	Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2125-2132	2.2	641
670	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3733-3739	2.2	486
669	CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MINT) Group. <i>Lancet Oncology, The</i> , 2011 , 12, 1013-22	21.7	485
668	Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. <i>Leukemia</i> , 2007 , 21, 340-50	10.7	470
667	Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1182-9	2.2	442
666	Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. <i>Blood</i> , 2003 , 101, 2489-95	2.2	424
665	Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5156-64	2.2	378
664	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 378, 331-344	59.2	378
663	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1428-1439	2.2	377
662	T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. <i>Gastroenterology</i> , 2002 , 122, 1286-94	13.3	345
661	An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. <i>Annals of Oncology</i> , 2011 , 22, 1622-1627	10.3	318
660	Brentuximab vedotin or physician choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet, The</i> , 2017 , 390, 555-566	40	303

659	Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2472-9	2.2	295
658	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 229-240	4.0	283
657	ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. <i>New England Journal of Medicine</i> , 2011 , 365, 203-12	59.2	282
656	Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4293-7	2.2	244
655	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1192-1204	21.7	239
654	Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2018 , 391, 659-667	4.0	231
653	Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1254	2.2	229
652	Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3898-3905	2.2	228
651	Peripheral T-cell lymphoma. <i>Blood</i> , 2011 , 117, 6756-67	2.2	228
650	Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. <i>Journal of Clinical Investigation</i> , 2007 , 117, 823-34	15.9	228
649	Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. <i>Cancer</i> , 2011 , 117, 5058-66	6.4	226
648	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2013 , 24, 857-77	10.3	225
647	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015 , 373, 1733-47	59.2	215
646	Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2197-203	2.2	215
645	Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2017 , 130, 267-270	2.2	201
644	Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2603-6	2.2	194
643	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1285-1295	2.2	188
642	Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. <i>Cancer Research</i> , 2007 , 67, 10703-10	10.1	187

641	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 942-950	2.2	175
640	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017 , 129, 1380-1388	2.2	167
639	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 126, 1921-4	2.2	167
638	Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. <i>Annals of Oncology</i> , 2017 , 28, 2169-2178	10.3	157
637	Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. <i>Blood</i> , 2007 , 110, 54-8	2.2	156
636	Treatment and Clinical Management of Primary Mediastinal Large B-Cell Lymphoma With Sclerosis: MACOP-B Regimen and Mediastinal Radiotherapy Monitored by 67Gallium Scan in 50 Patients. <i>Blood</i> , 1999 , 94, 3289-3293	2.2	153
635	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017 , 28, 1436-1447	10.3	148
634	Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. <i>Blood</i> , 2019 , 134, 1144-1153	2.2	148
633	Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. <i>Annals of Oncology</i> , 2010 , 21, 860-863	10.3	147
632	Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1376-82	2.2	147
631	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. <i>Blood</i> , 2002 , 99, 856-62	2.2	147
630	Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1781-7	2.2	143
629	Hodgkin lymphoma: the pathologist's viewpoint. <i>Journal of Clinical Pathology</i> , 2002 , 55, 162-76	3.9	143
628	Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MINT) study. <i>Lancet Oncology</i> , 2008 , 9, 137-44	21.7	139
627	Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. <i>American Journal of Pathology</i> , 2003 , 162, 243-53	5.8	137
626	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. <i>Leukemia</i> , 2018 , 32, 1768-1777	10.7	136
625	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , 2014 , 15, 730-7	21.7	135
624	Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3880-6	2.2	134

623	The role of positron emission tomography (PET) in the management of lymphoma patients. <i>Annals of Oncology</i> , 1999 , 10, 1181-4	10.3	131
622	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3467-74	2.2	129
621	Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. <i>Cancer</i> , 2005 , 104, 2437-41	6.4	129
620	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. <i>Blood</i> , 2018 , 132, 2115-2124	2.2	127
619	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017 , 129, 553-560	2.2	126
618	DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 912-922	2.2	125
617	Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. <i>Haematologica</i> , 2002 , 87, 1258-64	6.6	124
616	Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2654-61	2.2	123
615	[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1769-75	2.2	120
614	Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. <i>Annals of Oncology</i> , 2006 , 17, 1296-300	10.3	118
613	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3291-3299	2.2	116
612	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015 , 126, 950-6	2.2	111
611	High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study. <i>Journal of Clinical Oncology</i> , 1996 , 14, 534-42	2.2	110
610	Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1255-62	2.2	109
609	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). <i>Lancet Haematology</i> , 2019 , 6, e254-e265	14.6	108
608	Consensus conference on the management of tumor lysis syndrome. <i>Haematologica</i> , 2008 , 93, 1877-85	6.6	106
607	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2013 , 24, 2108-12	10.3	104
606	Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. <i>Annals of Oncology</i> , 1997 , 8, 583-92	10.3	104

605	Early interim 18F-FDG PET in Hodgkin lymphoma: evaluation on 304 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 4-12	8.8	102
604	Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3019-25 ²	2.2	102
603	Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1376-85	2.2	101
602	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv30-iv40	10.3	99
601	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017 , 23, 4127-4137	12.9	98
600	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013 , 24 Suppl 6, vi149-54	10.3	98
599	Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. <i>Annals of Oncology</i> , 1998 , 9, 1351-3	10.3	96
598	PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013). <i>Blood</i> , 2014 , 124, 290-290	2.2	95
597	Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. <i>Annals of Oncology</i> , 2013 , 24, 2892-7	10.3	93
596	Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 462-6	2	92
595	Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. <i>Blood</i> , 2005 , 105, 3428-33	2.2	88
594	Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. <i>British Journal of Cancer</i> , 2004 , 91, 850-4	8.7	87
593	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014 , 89, 480-6	7.1	86
592	Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. <i>Lancet Oncology, The</i> , 2012 , 13, 696-706	21.7	85
591	A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. <i>Haematologica</i> , 2012 , 97, 1085-91	6.6	85
590	Anaplastic large cell lymphoma (CD30 +/Ki-1+): results of a prospective clinico-pathological study of 69 cases. <i>British Journal of Haematology</i> , 1994 , 86, 513-23	4.5	85
589	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2011 , 12, 773-84	21.7	84
588	CD30 expression in peripheral T-cell lymphomas. <i>Haematologica</i> , 2013 , 98, e81-2	6.6	83

587	Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 773-9	2.2	79
586	Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 2015 , 3,		78
585	Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1993 , 4, 575-8	10.3	78
584	Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2008 , 112, 325-325	2.2	78
583	Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. <i>Cancer</i> , 2012 , 118, 434-437	6.4	77
582	Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. <i>Cancer</i> , 2004 , 100, 2190-4	6.4	76
581	Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. <i>Nuclear Medicine Communications</i> , 2005 , 26, 689-94	1.6	75
580	Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. <i>Journal of Clinical Oncology</i> , 1996 , 14, 955-62	2.2	74
579	Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). <i>Lancet Oncology</i> , 2008 , 9, 352-8	21.7	73
578	Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. <i>Leukemia and Lymphoma</i> , 1999 , 32, 571-6	1.9	72
577	Myeloperoxidase expression by histiocytes in Kikuchi's and Kikuchi-like lymphadenopathy. <i>American Journal of Pathology</i> , 2001 , 159, 915-24	5.8	71
576	Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. <i>Cancer</i> , 2012 , 118, 5830-9	6.4	70
575	Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2007 , 48, 708-15	1.9	70
574	Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. <i>Annals of Oncology</i> , 2009 , 20, 1993-9	10.3	69
573	Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. <i>Haematologica</i> , 2005 , 90, 702-3	6.6	68
572	In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2705-11	2.2	67
571	The PROCLIP international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>British Journal of Dermatology</i> , 2019 , 181, 350-357	4	66
570	Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. <i>Haematologica</i> , 2007 , 92, 771-7	6.6	65

569	Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. <i>Histopathology</i> , 2002 , 41, 482-509	7.3	65
568	Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. <i>Journal of Clinical Oncology</i> , 1993 , 11, 925-30	2.2	65
567	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. <i>Lancet Haematology</i> , 2020 , 7, e112-e121	14.6	65
566	Mycosis fungoides. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 65, 172-82	7	64
565	Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3081-3089	2.2	63
564	Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4252-8	2.2	63
563	Primary bone lymphoma: experience with 52 patients. <i>Haematologica</i> , 2003 , 88, 280-5	6.6	63
562	Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2018 , 29, 1266-1272	10.3	62
561	Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2008 , 113, 2496-503	6.4	62
560	Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. <i>Clinical Cancer Research</i> , 2010 , 16, 3648-58	12.9	61
559	Enteropathy-associated T-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 79, 84-90	7	61
558	Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 381-5		61
557	Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. <i>British Journal of Haematology</i> , 1995 , 89, 780-9	4.5	61
556	Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. <i>Haematologica</i> , 2005 , 90, 225-31	6.6	61
555	Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015 , 26 Suppl 5, v100-7	10.3	60
554	A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. <i>Annals of Oncology</i> , 2008 , 19, 769-73	10.3	60
553	Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. <i>Blood</i> , 2017 , 129, 2328-2330	2.2	59
552	Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. <i>Haematologica</i> , 2009 , 94, 550-65	6.6	59

551	Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. <i>Haematologica</i> , 2008 , 93, 1033-8	6.6	59
550	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. <i>Annals of Oncology</i> , 2017 , 28, 2517-2525	10.3	58
549	Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 613-623	2.2	58
548	Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2008 , 93, 1364-71	6.6	58
547	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013 , 98, 1232-6	6.6	57
546	Expression of CD52 in peripheral T-cell lymphoma. <i>Haematologica</i> , 2007 , 92, 566-7	6.6	57
545	Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients. <i>Leukemia and Lymphoma</i> , 2003 , 44, 821-4	1.9	57
544	Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update. <i>Leukemia and Lymphoma</i> , 2016 , 57, 766-82	1.9	56
543	Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. <i>Cancer Treatment Reviews</i> , 2014 , 40, 1080-8	14.4	56
542	Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). <i>Annals of Oncology</i> , 2011 , 22, 689-695	10.3	56
541	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2021 , 22, 790-800	21.7	56
540	Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. <i>Lancet Oncology</i> , 2005 , 6, 440	21.7	55
539	¹⁸ F-FDG PET in malignant lymphoma: significance of positive findings. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005 , 32, 749-56	8.8	54
538	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020 , 135, 735-742	2.2	54
537	Peripheral T-cell lymphoma--not otherwise specified. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 79, 321-9	7	53
536	Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. <i>Journal of Clinical Pathology</i> , 2008 , 61, 1160-7	3.9	53
535	Primary non-Hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage II. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 59, 760-4	4	53
534	The many faces of marginal zone lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2012 , 2012, 426-432	3.1	52

533	Fludarabine treatment in resistant Waldenstrom's macroglobulinemia. <i>European Journal of Haematology</i> , 1995 , 54, 120-3	3.8	52
532	Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. <i>Haematologica</i> , 2017 , 102, e156-e159	6.6	51
531	The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). <i>Annals of Oncology</i> , 2014 , 25, 442-7	10.3	51
530	Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2011 , 117, 1010-8	6.4	51
529	Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. <i>Clinical Cancer Research</i> , 2010 , 16, 3998-4004	12.9	51
528	Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. <i>Haematologica</i> , 2004 , 89, 309-13	6.6	51
527	Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. <i>Leukemia and Lymphoma</i> , 1996 , 23, 577-82	1.9	50
526	Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. <i>American Journal of Hematology</i> , 2020 , 95, 362-371	7.1	50
525	The landscape of new drugs in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 335-346	19.4	49
524	Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1936-44	8.9	49
523	Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays. <i>Leukemia</i> , 2012 , 26, 499-508	10.7	49
522	Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. <i>Journal of Clinical Oncology</i> , 1998 , 16, 1532-7	2.2	49
521	18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2096-101	1.9	48
520	Pathobiology of primary mediastinal B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2003 , 44 Suppl 3, S21-6	1.9	48
519	Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?. <i>British Journal of Haematology</i> , 1991 , 79 Suppl 1, 48-51	4.5	47
518	Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015 , 6, 6553-69	3.3	47
517	Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. <i>Annals of Oncology</i> , 2018 , 29, 2363-2370	10.3	47
516	The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. <i>Leukemia</i> , 2004 , 18, 1215-22	10.7	46

515	Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper. <i>Hematological Oncology</i> , 2019 , 37, 3-14	1.3	46
514	Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. <i>British Journal of Dermatology</i> , 2016 , 175, 80-8	4	45
513	Rituximab in primary conjunctiva lymphoma. <i>Leukemia Research</i> , 2005 , 29, 107-8	2.7	45
512	The role of mitoxantrone in the treatment of indolent lymphomas. <i>Oncologist</i> , 2005 , 10, 150-9	5.7	45
511	Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics. <i>Journal of Clinical Pathology</i> , 2002 , 55, 684-8	3.9	45
510	Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure. <i>Cancer</i> , 1994 , 74, 1792-800	6.4	45
509	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , 2016 , 3, e467-e479	14.6	44
508	Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1585-8	1.9	43
507	Peripheral T-cell lymphoma, not otherwise specified. <i>Blood</i> , 2017 , 129, 1103-1112	2.2	42
506	Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems. <i>Cancer</i> , 2001 , 91, 1467-78	6.4	42
505	A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. <i>Cancer</i> , 2008 , 112, 856-62	6.4	41
504	Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. <i>Blood Cancer Journal</i> , 2014 , 4, e236	7	40
503	Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. <i>Haematologica</i> , 2005 , 90, 341-7	6.6	40
502	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Leukemia</i> , 2019 , 33, 2762-2766	10.7	39
501	The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. <i>British Journal of Haematology</i> , 2015 , 171, 215-226	4.5	39
500	The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. <i>British Journal of Haematology</i> , 2011 , 154, 477-81	4.5	39
499	Nongastrointestinal mucosa-associated lymphoid tissue (MALT) lymphomas: clinical and therapeutic features of 24 localized patients. <i>Annals of Oncology</i> , 1997 , 8, 883-6	10.3	39
498	Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1994 , 88, 770-7	4.5	39

497	The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015 , 90, 499-503	7.1	38
496	Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2018 , 132, 179-186	2.2	38
495	Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. <i>Cancer</i> , 2010 , 116, 4788-92	6.4	38
494	Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1997 , 8, 379-83	10.3	37
493	Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. <i>Leukemia</i> , 1997 , 11, 629-32	10.7	37
492	The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. <i>Cancer</i> , 2004 , 101, 1824-34	6.4	37
491	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018 , 36, 624-632	1.3	36
490	Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7, 291-5		36
489	The importance of endoscopic ultrasonography in the management of low-grade gastric mucosa-associated lymphoid tissue lymphoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16, 1715-22	6.1	36
488	Lymphoproliferative lung disorders. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005 , 26, 490-501	3.9	36
487	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2021 , 22, 512-524	21.7	36
486	Umbralisib, a Dual PI3K/CK1 Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1609-1618	2.2	36
485	A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG). <i>Hematological Oncology</i> , 2016 , 34, 177-183	1.3	36
484	Expression of B-lymphocyte-associated transcription factors in human T-cell neoplasms. <i>American Journal of Pathology</i> , 2003 , 162, 861-71	5.8	34
483	Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). <i>Annals of Hematology</i> , 2012 , 91, 1013-22	3	33
482	MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. <i>Annals of Oncology</i> , 2010 , 21, 1173-1178	10.3	33
481	Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. <i>British Journal of Haematology</i> , 2014 , 166, 69-76	4.5	32
480	Pyothorax-associated lymphoma: description of the first two cases detected in Italy. <i>Annals of Oncology</i> , 1997 , 8, 1133-8	10.3	32

479	Lymphoma: diagnosis, staging, natural history, and treatment strategies. <i>Seminars in Oncology</i> , 2005 , 32, S4-10	5.5	32
478	Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells. <i>American Journal of Hematology</i> , 1994 , 47, 301-6	7.1	32
477	Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. <i>Haematologica</i> , 2002 , 87, 816-21	6.6	32
476	Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. <i>British Journal of Haematology</i> , 2013 , 162, 639-47 ⁵	4.5	30
475	Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin lymphomas. <i>Annals of Oncology</i> , 2000 , 11, 363-5	10.3	30
474	Peripheral T cell lymphomas: from the bench to the clinic. <i>Nature Reviews Cancer</i> , 2020 , 20, 323-342	31.3	29
473	Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin lymphoma. <i>European Journal of Haematology</i> , 1995 , 54, 9-17 ^{3.8}	3.8	29
472	Primary Mediastinal B-cell lymphoma with sclerosis: clinical and therapeutic evaluation of 22 patients. <i>Leukemia and Lymphoma</i> , 1996 , 21, 311-6	1.9	29
471	Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1239-43 ^{1.9}	1.9	29
470	T-cell lymphomas in South america and europe. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012 , 34, 42-7		29
469	European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. <i>Haematologica</i> , 2016 , 101, e407-e410	6.6	28
468	SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. <i>American Journal of Hematology</i> , 2013 , 88, 185-92	7.1	28
467	FDG PET/CT predictive role in follicular lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 864-71	8.8	28
466	FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin lymphoma. <i>European Journal of Haematology</i> , 1995 , 55, 262-6	3.8	28
465	Efficacy of rituximab in hairy cell leukemia treatment. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3875-7	2.2	28
464	The many faces of marginal zone lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2012 , 2012, 426-32	3.1	28
463	First Analysis of the Completed Mabthera International (Mint) Trial in Young Patients with Low-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Addition of Rituximab to a CHOP-Like Regimen Significantly Improves Outcome of All Patients with the Identification of a Very Favorable Subgroup with IPI=0 and No Bulky Disease.. <i>Blood</i> , 2004 , 104, 157-157	2.2	28
462	Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2021 , 384, 1810-1823	59.2	28

461	Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. <i>Cancer Medicine</i> , 2016 , 5, 2740-2755	4.8	28
460	Management of nodal indolent (non marginal-zone) non-Hodgkin lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2005 , 90, 1236-57	6.6	28
459	Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2006 , 91, 96-103	6.6	28
458	Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. <i>Leukemia</i> , 2014 , 28, 1687-97	10.7	27
457	Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up. <i>Journal of Clinical Oncology</i> , 2002 , 20, 638-646	2.2	27
456	Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. <i>Cancer Treatment Reviews</i> , 2017 , 60, 120-129	14.4	26
455	Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. <i>British Journal of Haematology</i> , 2014 , 164, 710-6	4.5	26
454	Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 1995 , 19, 329-35	1.9	26
453	A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 38	22.4	26
452	Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. <i>Hematological Oncology</i> , 2013 , 31, 183-8	1.3	25
451	FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. <i>Annals of Oncology</i> , 2010 , 21, 1877-1883	10.3	25
450	Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 359-69	7	24
449	The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients. <i>Hematological Oncology</i> , 2015 , 33, 145-50	1.3	24
448	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 75-85	2	24
447	Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 228-40	7	24
446	Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 715-8	7.3	24
445	In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 125	22.4	24
444	Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 321-5	2	24

443	Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 1993 , 51, 93-7	3.8	24
442	FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects. <i>European Journal of Haematology</i> , 1996 , 56, 308-12	3.8	24
441	A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by α -ibrutumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. <i>Annals of Oncology</i> , 2012 , 23, 415-20	10.3	24
440	Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. <i>European Journal of Cancer</i> , 2008 , 44, 366-73	7.5	24
439	Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2014 , 124, 4457-4457	2.2	24
438	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 678-689	21.7	24
437	Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2006 , 91, 1662-73	6.6	24
436	A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014 , 167, 466-77	4.5	23
435	2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. <i>European Journal of Haematology</i> , 1997 , 58, 46-50	3.8	23
434	Treatment of hairy-cell leukaemia with alpha-interferon (alpha-IFN). <i>European Journal of Cancer & Clinical Oncology</i> , 1988 , 24, 195-200		23
433	18F-FDG PET Early After Radiotherapy in Lymphoma Patients. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004 , 19, 606-612	3.9	23
432	KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. <i>Blood Advances</i> , 2020 , 4, 2617-2622	7.8	22
431	CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?. <i>American Journal of Hematology</i> , 2017 , 92, E1-E2	7.1	22
430	Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. <i>Oncologist</i> , 2014 , 19, 746-50	5.7	22
429	Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 1224-32	4.7	22
428	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 42-49	4	21
427	Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. <i>Hematological Oncology</i> , 2013 , 31, 223-4	1.3	21
426	Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 314-20	2	20

425	Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 1996 , 22, 131-5	1.9	20
424	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021 , 8, e410-e421	14.6	20
423	Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. <i>British Journal of Haematology</i> , 2016 , 174, 692-9	4.5	20
422	Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2017 , 23, 3552-3556	12.9	19
421	Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab. <i>Haematologica</i> , 2016 , 101, e385-6	6.6	19
420	The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1911-7	1.9	19
419	Cryptococcal meningitis and intracranial tuberculoma in a patient with Waldenström's macroglobulinemia treated with fludarabine. <i>Leukemia and Lymphoma</i> , 1998 , 28, 617-20	1.9	19
418	PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment. <i>Blood</i> , 2015 , 126, 584-584	2.2	19
417	Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients. <i>Oncologist</i> , 2015 , 20, 1413-6	5.7	18
416	GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers. <i>BMC Cancer</i> , 2012 , 12, 586	4.8	18
415	Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma: experience with 27 patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 404-8	2	17
414	Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 214-27	7	17
413	MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients. <i>Haematologica</i> , 2019 , 104, e25-e28	6.6	17
412	Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. <i>Cancer Treatment Reviews</i> , 2017 , 61, 61-69	14.4	17
411	Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1671-6	1.9	17
410	Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. <i>Hematological Oncology</i> , 2013 , 31, 179-82	1.3	17
409	Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 72, 21-44	7	17
408	Aggressive lymphoma: improving treatment outcome with rituximab. <i>Anti-Cancer Drugs</i> , 2002 , 13 Suppl 2, S43-50	2.4	17

407	Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 1994 , 13, 95-7	1.9	17
406	Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 1218-1218	2.2	17
405	NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE PHASE 2 CHECKMATE 205 TRIAL. <i>Hematological Oncology</i> , 2017 , 35, 135-136	1.3	16
404	Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. <i>Rheumatology International</i> , 2012 , 32, 2209-13	3.6	16
403	Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin lymphoma. <i>European Journal of Haematology</i> , 1996 , 57, 335-40	3.8	16
402	Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1354-60	8.9	16
401	Indolent lymphoma: the pathologist's viewpoint. <i>Annals of Oncology</i> , 2004 , 15, 12-8	10.3	16
400	Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2212-22	2.2	16
399	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <i>European Journal of Cancer</i> , 2016 , 60, 154-65	7.5	16
398	Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. <i>British Journal of Haematology</i> , 2017 , 178, 588-591	4.5	15
397	Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2318-21	1.9	15
396	Novel therapies for aggressive B-cell lymphoma. <i>Advances in Hematology</i> , 2012 , 2012, 302570	1.5	15
395	Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7, 566-72		15
394	Traditional treatment approaches in B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2003 , 44 Suppl 4, S6-14	1.9	15
393	The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. <i>British Journal of Haematology</i> , 2002 , 118, 218-28	4.5	15
392	Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin lymphoma patients. <i>Annals of Oncology</i> , 2002 , 13, 1364-9	10.3	15
391	Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 1999 , 33, 147-53	1.9	15
390	MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 1995 , 16, 457-63	1.9	15

389	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021 , 35, 2672-2683	15	15
388	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 104, 65-70	7	15
387	Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 35	22.4	15
386	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1814-1828	1.9	15
385	Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. <i>Haematologica</i> , 2005 , 90, 1283-4	6.6	15
384	Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1585-92	8.8	14
383	SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. <i>Annals of Oncology</i> , 2014 , 25, 2339-2350	10.3	14
382	Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. <i>Journal of Hematology and Oncology</i> , 2012 , 5, 67	22.4	14
381	Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab. <i>Clinical Cancer Research</i> , 2013 , 19, 2551-61	12.9	14
380	T-cell prolymphocytic leukaemia: does the expression of CD8+ phenotype justify the identification of a new subtype? Description of two cases and review of the literature. <i>Annals of Oncology</i> , 1999 , 10, 649-53	10.3	14
379	The inhibitory effect of serum from hairy-cell leukaemia patients on normal progenitor cells may disappear following prolonged treatment with alpha-interferon. <i>British Journal of Haematology</i> , 1989 , 72, 497-501	4.5	14
378	First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962). <i>Blood</i> , 2015 , 126, 341-341	2.2	14
377	Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. <i>Oncologist</i> , 2016 , 21, 1436-1441	5.7	14
376	⁹⁰ yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years. <i>Cancer Medicine</i> , 2016 , 5, 1093-7	4.8	14
375	The role of transplantation in Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019 , 184, 93-104	4.5	14
374	Angioimmunoblastic T-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2017 , 31, 223-238	3.1	13
373	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019 , 9, 48	7	13
372	Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 258-65	2	13

371	Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 287-9	2	13
370	PET in T-Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2011 , 6, 241-4	4.4	13
369	Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience. <i>Leukemia and Lymphoma</i> , 2009 , 50, 481-4	1.9	13
368	Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. <i>Cancer</i> , 2010 , 116, 5667-75	6.4	13
367	Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. <i>Lancet Oncology, The</i> , 2004 , 5, 381-3	21.7	13
366	Primary gastric lymphoma: a clinical and therapeutic evaluation of 82 patients. <i>Leukemia and Lymphoma</i> , 1995 , 19, 461-6	1.9	13
365	Hodgkin disease (HD): a historical perspective. <i>European Journal of Cancer & Clinical Oncology</i> , 1986 , 22, 1315-23		13
364	Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). <i>Blood</i> , 2015 , 126, 3986-3986	2.2	13
363	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 3502-3502	2.2	13
362	Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8503-8503	2.2	13
361	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021 , 35, 1864-1872	10.7	13
360	Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. <i>American Journal of Hematology</i> , 2017 , 92, E575-E583	7.1	12
359	Bendamustine: role and evidence in lymphoma therapy, an overview. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1471-8	1.9	12
358	Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2012 , 53, 789-95	1.9	12
357	Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. <i>British Journal of Haematology</i> , 2013 , 163, 681-3	4.5	12
356	Primary mediastinal DLBCL: evolving biologic understanding and therapeutic strategies. <i>Current Oncology Reports</i> , 2011 , 13, 407-15	6.3	12
355	Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010 , 10, 258-61	2	12
354	Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). <i>Annals of Oncology</i> , 2012 , 23, 805-807	10.3	12

353	Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. <i>Leukemia and Lymphoma</i> , 2008 , 49, 159-62 ¹⁹	12
352	EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2006 , 7, 152-4	12
351	Diffuse large B-cell lymphoma with primary retroperitoneal presentation: clinico-pathologic study of nine cases. <i>Annals of Oncology</i> , 2001 , 12, 1445-53	10.3 12
350	High complete remission rate in hairy cell leukemia treated with 2-chlorodeoxyadenosine. <i>Leukemia and Lymphoma</i> , 1993 , 11, 399-404	1.9 12
349	Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment. <i>Leukemia and Lymphoma</i> , 1992 , 7, 103-7 ¹⁹	12
348	Reduced hematologic response to alpha-interferon therapy in patients with hairy cell leukemia showing a peculiar immunologic phenotype. <i>Cancer</i> , 1990 , 65, 2233-6	6.4 12
347	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. <i>Oncotarget</i> , 2017 , 8, 91703-91710	3.3 12
346	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. <i>Lancet Haematology</i> , 2020 , 7, e649-e659	14.6 12
345	Possible novel agents in marginal zone lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2017 , 30, 149-157	4.2 11
344	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. <i>European Journal of Cancer</i> , 2020 , 133, 120-130	7.5 11
343	Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. <i>Annals of Hematology</i> , 2014 , 93, 1853-7	3 11
342	Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 507-13	2 11
341	Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 493-5	2 11
340	Non-Hodgkin's lymphoma: the evolving role of purine analogues. <i>Best Practice and Research in Clinical Haematology</i> , 2002 , 15, 505-16	4.2 11
339	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. <i>Blood</i> , 2018 , 132, 228-228	2.2 11
338	Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8519-8519	2.2 11
337	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , 2020 , 9, 6565-6575	4.8 11
336	Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients. <i>Hematological Oncology</i> , 2015 , 33, 141-6	1.3 10

335	Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. <i>Haematologica</i> , 2016 , 101, e139-41	6.6	10
334	The unique biology and treatment of primary mediastinal B-cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018 , 31, 241-250	4.2	10
333	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. <i>Leukemia Research</i> , 2014 , 38, 1269-77	2.7	10
332	Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 1997 , 59, 82-8	3.8	10
331	Targeted molecular therapy in peripheral T-cell lymphomas. <i>Expert Review of Hematology</i> , 2011 , 4, 551-628		10
330	Biology and treatment of follicular lymphoma. <i>Expert Review of Hematology</i> , 2009 , 2, 533-47	2.8	10
329	Difficult diagnostic and therapeutic cases: CASE 1. true thymic hyperplasia in a patient treated for T-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 953-4	2.2	10
328	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.. <i>Nature Medicine</i> , 2021 ,	50.5	10
327	A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis. <i>Blood</i> , 2019 , 134, 4078-4078	2.2	10
326	Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results. <i>Blood Cancer Journal</i> , 2016 , 6, e425	7	9
325	PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE-087 STUDY. <i>Hematological Oncology</i> , 2017 , 35, 136-137	1.3	9
324	The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients. <i>BMC Cancer</i> , 2017 , 17, 276	4.8	9
323	Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. <i>American Journal of Hematology</i> , 2013 , 88, E273-6	7.1	9
322	Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 1997 , 26, 343-8	1.9	9
321	VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2167-71	1.9	9
320	FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report. <i>British Journal of Haematology</i> , 1994 , 86, 394-6	4.5	9
319	Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study. <i>Blood</i> , 2018 , 132, 2932-2932	2.2	9
318	Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2014 , 124, 1708-1708	2.2	9

317	Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study. <i>Blood</i> , 2017 , 130, 650-650	2.2	9
316	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. <i>American Journal of Hematology</i> , 2020 , 95, 1553-1561	7.1	9
315	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 6323-6332	12.9	9
314	The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 12-25	1.9	8
313	Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1695-701	4.7	8
312	High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience. <i>BMC Cancer</i> , 2015 , 15, 879	4.8	8
311	Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. <i>Leukemia and Lymphoma</i> , 2014 , 55, 988-98	1.9	8
310	CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. <i>Journal of Neuro-Oncology</i> , 2009 , 95, 135-139	4.8	8
309	Radioimmunotherapy with (90)Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network. <i>Bone Marrow Transplantation</i> , 2011 , 46, 901-3	4.4	8
308	Persistent agmination of lymphomatoid papulosis: an ongoing debate. <i>Dermatology</i> , 2012 , 225, 131-4	4.4	8
307	Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion. <i>British Journal of Haematology</i> , 2006 , 134, 356	4.5	8
306	MACOP-B regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin lymphoma patients: 14-year update results. <i>Leukemia and Lymphoma</i> , 2001 , 42, 989-95	1.9	8
305	A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS8615-TPS8615	2.2	8
304	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018 , 9, 23443-23450	3.3	8
303	Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. <i>Blood Advances</i> , 2021 , 5, 823-828	7.8	8
302	The emerging role of GSK-3 in the pathobiology of classical Hodgkin lymphoma. <i>Histopathology</i> , 2017 , 71, 72-80	7.3	7
301	Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2705-2711	1.9	7
300	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , 2019 , 94, 628-634	7.1	7

299	Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016 , 30, 1261-1275	3.1	7
298	Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. <i>HIV Medicine</i> , 2018 , 19, 523	2.7	7
297	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2017 , 102, 1931-1935	6.6	7
296	Long-term follow-up studies in hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50 Suppl 1, 23-6	1.9	7
295	FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia. <i>Leukemia and Lymphoma</i> , 1996 , 22, 173-6	1.9	7
294	Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2003 , 44 Suppl 3, S115-22	1.9	7
293	Challenging paradigms in lymphoma treatment. <i>Annals of Oncology</i> , 2004 , 15, 703-11	10.3	7
292	Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin lymphomas. <i>Cancer Chemotherapy and Pharmacology</i> , 1989 , 23, 123-5	3.5	7
291	Lymphoblastic lymphoma in adolescents and adults. Clinical, pathological and prognostic evaluation. <i>European Journal of Cancer & Clinical Oncology</i> , 1986 , 22, 1503-10		7
290	Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 1528-1528	2.2	7
289	Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma. <i>Blood</i> , 2015 , 126, 3935-3935	2.2	7
288	RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2000-2000	2.2	7
287	Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019 , 24, 1246-1252	5.7	7
286	RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 6124-6134	12.9	7
285	Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma. <i>Acta Haematologica</i> , 2017 , 137, 191-194	2.7	6
284	Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. <i>Leukemia Research</i> , 2019 , 81, 88-94	2.7	6
283	Nonpegylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. <i>Hematological Oncology</i> , 2020 , 38, 478-485	1.3	6
282	Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma. <i>Immunotherapy</i> , 2018 , 10, 699-711	3.8	6

281	SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2012 , 36, 459-66	2.7	6
280	Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. <i>Nuclear Medicine Communications</i> , 2008 , 29, 705-10	1.6	6
279	Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. <i>European Journal of Haematology</i> , 2006 , 77, 109-13	3.8	6
278	B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens. <i>Journal of Clinical Pathology</i> , 2007 , 60, 627-32	3.9	6
277	Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. <i>Leukemia and Lymphoma</i> , 2005 , 46, 1449-54	1.9	6
276	Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2005 , 46, 1437-40	1.9	6
275	Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases. <i>Transplantation Proceedings</i> , 2006 , 38, 1477-80	1.1	6
274	Rituximab in heavily pretreated cutaneous B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1637-8	1.9	6
273	Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1815-9	1.9	6
272	Histopathology of B-cell chronic lymphocytic leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004 , 18, 807-26, viii	3.1	6
271	Cep Regimen (Cenu, Etoposide, Prednimustine) for Relapsed/Refractory Hodgkin's Disease. <i>Tumori</i> , 1994 , 80, 438-442	1.7	6
270	Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).. <i>Blood</i> , 2009 , 114, 1676-1676	2.2	6
269	ROCHOP study: A phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS8616-TPS8616	2.2	6
268	Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 950-954	1.9	6
267	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021 , 148, 411-421	7.5	6
266	Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper. <i>European Journal of Haematology</i> , 2016 , 97, 554-561	3.8	6
265	Utility of surgical resection with or without radiation therapy in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma. <i>Haematologica</i> , 2003 , 88, 830-1	6.6	6
264	Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 1661-1671	8.8	5

263	Consolidation with Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2689-2696	1.9	5
262	Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 3058-3065	8.8	5
261	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2904-2910	1.9	5
260	Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2990-2993	1.9	5
259	Results in hairy-cell leukemia patients treated with alpha-interferon: predictive prognostic factors. <i>European Journal of Haematology</i> , 1992 , 49, 133-7	3.8	5
258	Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology. <i>American Journal of Hematology</i> , 2010 , 85, 147-55	7.1	5
257	Salvage chemotherapy in follicular non-Hodgkin lymphoma: focus on tolerability. <i>Clinical Lymphoma and Myeloma</i> , 2006 , 7, 115-24		5
256	Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers. <i>Annals of Oncology</i> , 2001 , 12, 1479-84	10.3	5
255	ABVD and radiation therapy as first-line treatment in advanced Hodgkin disease. <i>Leukemia and Lymphoma</i> , 1999 , 32, 553-9	1.9	5
254	Adult Burkitt lymphoma: clinical and prognostic evaluation of 20 patients. <i>Leukemia and Lymphoma</i> , 1994 , 14, 465-70	1.9	5
253	Massive mediastinal involvement in stage I-II Hodgkin disease: response to combined modality treatment. <i>Leukemia and Lymphoma</i> , 1992 , 8, 81-5	1.9	5
252	Continuous infusion of interleukin-2 in two relapsed high grade non-Hodgkin lymphoma patients: effectiveness and tolerability. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 521-2		5
251	PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2008 , 112, 261-261	2.2	5
250	A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. <i>Blood</i> , 2010 , 116, 2462-2462	2.2	5
249	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) after Treatment with Programmed Cell Death 1 (PD-1) Inhibitors. <i>Blood</i> , 2015 , 126, 2018-2018	2.2	5
248	Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2021 ,	2.2	5
247	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. <i>Cell Reports Medicine</i> , 2020 , 1, 100158	18	5
246	The classic prognostic factors in advanced Hodgkin lymphoma patients are losing their meaning at the time of Pet-guided treatments. <i>Annals of Hematology</i> , 2020 , 99, 277-282	3	5

245	The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience. <i>American Journal of Hematology</i> , 2021 , 96, 1204-1210	7.1	5
244	Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: a case report and review of the literature. <i>Tumori</i> , 2016 , 102,	1.7	5
243	PRIMARY ANALYSIS RESULTS OF THE SINGLE-ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (L-MIND). <i>Hematological Oncology</i> , 2019 , 37, 173-174	1.3	5
242	EFFICACY AND SAFETY IN HIGH-RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB. <i>Hematological Oncology</i> , 2019 , 37, 387-389	1.3	5
241	Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry. <i>British Journal of Haematology</i> , 2019 , 184, 949-956	4.5	5
240	Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. <i>Leukemia</i> , 2021 ,	10.7	5
239	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. <i>Blood Advances</i> , 2021 , 5, 5098-5106	7.8	5
238	Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience. <i>Cancers</i> , 2021 , 13,	6.6	5
237	The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 226-229	1.9	4
236	Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and Sézary syndrome?. <i>European Journal of Dermatology</i> , 2017 , 27, 49-53	0.8	4
235	Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients. <i>Hematological Oncology</i> , 2020 , 38, 487-492	1.3	4
234	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2370-4	1.9	4
233	Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program. <i>Hematological Oncology</i> , 2018 , 36, 689-692	1.3	4
232	Is it really possible to cure hairy cell leukemia patients only with frontline therapy?. <i>Annals of Hematology</i> , 2014 , 93, 1565-9	3	4
231	Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, e119-22	2	4
230	High-dose therapy and stem cell transplantation. <i>Seminars in Hematology</i> , 2010 , 47 Suppl 1, S15-7	4	4
229	Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomycin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1824-9	1.9	4
228	Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. <i>Annals of Nuclear Medicine</i> , 2008 , 22, 429-32	2.5	4

227	Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. <i>Leukemia and Lymphoma</i> , 2005 , 46, 1839-41	1.9	4
226	Bilateral primary breast lymphoma: a case of local recurrence. <i>Leukemia and Lymphoma</i> , 2003 , 44, 737-8	1.9	4
225	18F-FDG PET early after radiotherapy in lymphoma patients. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004 , 19, 606-12	3.9	4
224	Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma. <i>The Hematology Journal</i> , 2004 , 5 Suppl 1, S38-49		4
223	High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience. <i>Leukemia and Lymphoma</i> , 2004 , 45, 321-6	1.9	4
222	Complications of cytotoxic chemotherapy in older patients: focus on myelotoxicity in lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 48, S27-31	7	4
221	Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease. <i>Leukemia and Lymphoma</i> , 1995 , 16, 511-3	1.9	4
220	Anthracycline containing regimens in intermediate grade lymphoma. Italian Cooperative Study Group on Intermediate Grade Malignant Lymphoma. <i>Leukemia and Lymphoma</i> , 1993 , 10 Suppl, 39-41	1.9	4
219	Radiotherapy in early stage Hodgkin's disease. <i>Leukemia and Lymphoma</i> , 1994 , 13, 285-9	1.9	4
218	Comparison of low-dose versus standard-dose alpha-interferon regimen in the hairy cell leukemia treatment. <i>Acta Haematologica</i> , 1991 , 85, 16-9	2.7	4
217	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204). <i>Blood</i> , 2020 , 136, 27-28	2.2	4
216	Phase II Study of Alemtuzumab Treatment in Patients with Pretreated T-Cell Lymphoma.. <i>Blood</i> , 2004 , 104, 4605-4605	2.2	4
215	A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Follicular Lymphoma (FL) Patients.. <i>Blood</i> , 2006 , 108, 2479-2479	2.2	4
214	A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma. <i>Blood</i> , 2010 , 116, 857-857	2.2	4
213	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. <i>Blood</i> , 2011 , 118, 294-294	2.2	4
212	A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL). <i>Blood</i> , 2014 , 124, 1763 ² -1763 ⁴		
211	A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8507-8507	2.2	4
210	Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study. <i>Annals of Hematology</i> , 2020 , 99, 283-291	3	4

209	Cutaneous adverse-events in patients treated with Ibrutinib. <i>Dermatologic Therapy</i> , 2020 , 33, e14190	2.2	4
208	Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma. <i>Cancer Medicine</i> , 2020 , 9, 7830-7836	4.8	4
207	A three-gene signature based on , and improves risk stratification in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021 , 106, 2405-2416	6.6	4
206	The importance of assessing blood tumour burden in cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2021 , 185, 19-25	4	4
205	Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution. <i>European Journal of Haematology</i> , 2021 , 106, 737-739	3.8	4
204	Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. <i>Blood Advances</i> , 2021 , 5, 3387-3396	7.8	4
203	The role of surgery for haematologic neoplasms of bone. <i>Acta Orthopaedica Belgica</i> , 2012 , 78, 382-92	1.3	4
202	Reporting real-life experience with drugs in lymphoma patients. <i>Hematological Oncology</i> , 2017 , 35, 909-910		3
201	Are Biosimilars the Future of Oncology and Haematology?. <i>Drugs</i> , 2019 , 79, 1609-1624	12.1	3
200	PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series. <i>Haematologica</i> , 2019 , 104, e521-e522	6.6	3
199	Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2247-2254	1.9	3
198	Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. <i>Experimental Hematology and Oncology</i> , 2015 , 4, 24	7.8	3
197	Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients. <i>Annals of Hematology</i> , 2021 , 100, 2261-2268	3	3
196	Y-ibrutumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study. <i>British Journal of Haematology</i> , 2020 , 189, e6-e9	4.5	3
195	Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. <i>European Journal of Haematology</i> , 2020 , 104, 499-508	3.8	3
194	Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report. <i>Tumori</i> , 2017 , 103, e41-e43	1.7	3
193	ALCL: is it now a curable disease?. <i>Blood</i> , 2017 , 130, 2691-2692	2.2	3
192	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). <i>Oncologist</i> , 2018 , 23, 1033-1038	5.7	3

191	Primary cutaneous peripheral T-cell lymphoma not otherwise specified a rare and aggressive lymphoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, e373-e376	4.6	3
190	Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: bridge to transplant. <i>Hematological Oncology</i> , 2018 , 36, 489-491	1.3	3
189	A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. <i>BMC Cancer</i> , 2018 , 18, 645	4.8	3
188	Spontaneous remission of follicular lymphoma. <i>Hematological Oncology</i> , 2019 , 37, 626-627	1.3	3
187	Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. <i>British Journal of Haematology</i> , 2014 , 166, 625-8	4.5	3
186	Critical value of laparotomy with splenectomy in stage III Hodgkin disease as restaging procedure after chemotherapy. <i>European Journal of Haematology</i> , 1988 , 41, 6-11	3.8	3
185	Thoughts on the eradication of Helicobacter pylori infection in localized gastric mucosa-associated lymphoid tissue lymphoma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2013-4	1.9	3
184	Discordant response to chemotherapy: an unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1048-52	1.9	3
183	Autologous hematopoietic stem cell transplantation in Non-Hodgkin lymphomas. <i>Acta Haematologica</i> , 2005 , 114, 255-9	2.7	3
182	2-Chlorodeoxyadenosine in psoriasis treatment. <i>Annals of Oncology</i> , 1995 , 6, 509	10.3	3
181	Ceop Regimen in the Treatment of Advanced Low-Grade Non-Hodgkin Lymphomas: Preliminary Report. <i>Tumori</i> , 1990 , 76, 533-536	1.7	3
180	The ECHELON-2 Trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.. <i>Annals of Oncology</i> , 2021 ,	10.3	3
179	Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study. <i>Blood</i> , 2011 , 118, 265-265	2.2	3
178	Combination of Epigenetic Agents Synergistically Reverse the Malignant Phenotype in Models of T-Cell Lymphoma. <i>Blood</i> , 2011 , 118, 2727-2727	2.2	3
177	The Role of Interim-PET and Final-PET in the Outcome of Peripheral T-Cell Lymphoma (PTCL) Treated At the Diagnosis with CHOP.. <i>Blood</i> , 2012 , 120, 2721-2721	2.2	3
176	Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi. <i>Blood</i> , 2013 , 122, 850-850	2.2	3
175	Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study. <i>Blood</i> , 2014 , 124, 3088-3088	2.2	3
174	Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study. <i>Blood</i> , 2015 , 126, 1541-1541	2.2	3

173	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study. <i>Blood</i> , 2015 , 126, 3946-3946	2.2	3
172	Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19554-e19554	2.2	3
171	PI3K Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients. <i>Cancers</i> , 2021 , 13,	6.6	3
170	Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma. <i>Cancer</i> , 2021 ,	6.4	3
169	Controversies in the Treatment of Peripheral T-cell Lymphoma. <i>HemaSphere</i> , 2020 , 4, e461	0.3	3
168	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2931-2938	1.9	3
167	Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience. <i>Hematological Oncology</i> , 2020 , 38, 737-741	1.3	3
166	Vemurafenib mucosal side-effect. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 1053-5	4.6	3
165	New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia. <i>British Journal of Dermatology</i> , 2019 , 180, 1535-1536	4	3
164	Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e595-e596	2	2
163	Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma. <i>International Reviews of Immunology</i> , 2019 , 38, 79-91	4.6	2
162	How do we sequence therapy for marginal zone lymphomas?. <i>Hematology American Society of Hematology Education Program</i> , 2020 , 2020, 295-305	3.1	2
161	Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry. <i>Annals of Hematology</i> , 2020 , 99, 1073-1079	3	2
160	Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis. <i>Hematological Oncology</i> , 2018 , 36, 136-143	1.3	2
159	V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia. <i>OncoTargets and Therapy</i> , 2019 , 12, 4807-4812	4.4	2
158	Role of autologous stem cell transplantation in T-cell lymphoma patients: a single institution retrospective analysis. <i>Hematological Oncology</i> , 2015 , 33, 164-5	1.3	2
157	An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013 2015 , 3,		2
156	T-Cell Project: an international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2009 , 31,		2

155	CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. <i>Journal of Clinical Pathology</i> , 2011 , 64, 83-7	3.9	2
154	Primary gastric diffuse large-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1201-2	1.9	2
153	Phase II cooperative study with a new alkylating drug, PTT-119, in the treatment of non-Hodgkin's lymphomas. <i>Blut</i> , 1990 , 60, 172-6		2
152	Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma.. <i>Blood</i> , 2009 , 114, 1659-1659	2.2	2
151	Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study.. <i>Blood</i> , 2009 , 114, 1662-1662	2.2	2
150	Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).. <i>Blood</i> , 2009 , 114, 1675-1675	2.2	2
149	The Combination of Bortezomib and Rituximab Is Effective and Safe in Relapsed/Refractory Indolent Non Follicular and Mantle-Cell Non Hodgkin Lymphoma: a Phase II Multicenter Study by Intergruppo Italiano Linfomi.. <i>Blood</i> , 2009 , 114, 3758-3758	2.2	2
148	IHP Interpretation Criteria of Interim-PET Scan Confirms Prognostic Impact In Early Stage Hodgkin Lymphoma Patients without Bulky Disease. <i>Blood</i> , 2010 , 116, 3890-3890	2.2	2
147	Analysis of Toxicity and Efficacy of Subcutaneous Cladribine at Reduced or Standard Doses (Five Versus Seven Consecutive Days) In Patients with Hairy Cell Leukemia (HCL) In the ICGHCL2004 Protocol by the Italian Cooperative Group on Hcl. <i>Blood</i> , 2010 , 116, 701-701	2.2	2
146	Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group. <i>Blood</i> , 2012 , 120, 1566-1566	2.2	2
145	Lenalidomide Is Effective in Heavily Pretreated Non Hodgkin Lymphoma (NHL): Analysis of a Retrospective Data Collection. <i>Blood</i> , 2012 , 120, 3694-3694	2.2	2
144	Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012 , 120, 903-903	2.2	2
143	Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi. <i>Blood</i> , 2013 , 122, 3047-3047	2.2	2
142	Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial. <i>Blood</i> , 2014 , 124, 150-150	2.2	2
141	Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2014 , 124, 1755-1755	2.2	2
140	Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat. <i>Blood</i> , 2014 , 124, 3075-3075	2.2	2
139	The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015 , 126, 2735-2735	2.2	2
138	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. <i>Blood</i> , 2016 , 128, 2038-2038	2.2	2

137	Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	2
136	Cutaneous leukocytoclastic vasculitis in B-cell chronic lymphocytic leukemia patients. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019 , 154, 605-606	0.8	2
135	A Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma.. <i>Blood</i> , 2010 , 116, 2803-2803	2.2	2
134	Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP + ibrutinib. <i>British Journal of Haematology</i> , 2021 , 194, 83-91	4.5	2
133	Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1204-1213	1.9	2
132	Phosphatidyl-inositol 3-kinase inhibitors in the treatment of T-cell lymphomas. <i>Annals of Lymphoma</i> , 2018 , 1, 1-1	1.8	2
131	Plaques and tumors in a patient with refractory Sjögren syndrome treated with mogamulizumab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018 , 16, 1263-1265	1.2	2
130	Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2225-2238	4.6	2
129	Integrated safety analysis of umbralisib, a dual PI3K/CK1 inhibitor, in relapsed/refractory lymphoid malignancies. <i>Blood Advances</i> , 2021 , 5, 5332-5343	7.8	2
128	A 3-decade multicenter European experience with cladribine as upfront treatment in 384 hairy cell leukemia patients.. <i>Blood Advances</i> , 2022 ,	7.8	2
127	NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY. <i>Hematological Oncology</i> , 2019 , 37, 157-158	1.3	1
126	Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1969-74	1.9	1
125	Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report. <i>Acta Haematologica</i> , 2020 , 143, 594-597	2.7	1
124	Chronic lymphocytic leukemia focus in the context of a cardiac mass in a pretreated patient: an exceptional incidental finding. <i>Tumori</i> , 2020 , 106, NP29-NP32	1.7	1
123	Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin lymphoma. <i>Hematological Oncology</i> , 2016 , 34, 49-51	1.3	1
122	The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience. <i>American Journal of Hematology</i> , 2018 , 93, E209	7.1	1
121	A treatment for activated B-cell-like DLBCL?. <i>Lancet Oncology, The</i> , 2014 , 15, 916-7	21.7	1
120	L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) IN A SINGLE-ARM PHASE II STUDY. <i>Hematological Oncology</i> , 2017 , 35, 51-52	1.3	1

119	PET/CT-GUIDED BIOPSY FOR THE DIAGNOSIS OF LYMPHOMA. <i>Hematological Oncology</i> , 2017 , 35, 425-425	3.5	1
118	Prolonged bone marrow aplasia of refractory prolymphocytoid variant of B-cell chronic lymphocytic leukemia related to fludarabine treatment. <i>European Journal of Haematology</i> , 1994 , 53, 56-8	3.8	1
117	Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. <i>Clinical Nuclear Medicine</i> , 2009 , 34, 777-8	1.7	1
116	Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin lymphoma and Hodgkin disease: the Italian experience. <i>Annals of Oncology</i> , 2003 , 14 Suppl 1, i43-5	10.3	1
115	High-dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin lymphoma. <i>European Journal of Haematology</i> , 1986 , 37, 347-52	3.8	1
114	Primary Mediastinal Large B-Cell Lymphoma: Investigation On The Role Of Rituximab and PET During Treatment. <i>Blood</i> , 2013 , 122, 3046-3046	2.2	1
113	A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3116-TPS3116	2.2	1
112	Granulomatous tattoo reaction in a nivolumab-treated patient. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020 , 155, 530-532	0.8	1
111	Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia. <i>Hematological Oncology</i> , 2021 ,	1.3	1
110	Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021 ,	7.8	1
109	Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2015 , 126, 2725-2725	2.2	1
108	The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2011 , 118, 2732-2732	2.2	1
107	Idelalisib as a Bridge to Allogeneic Transplantation in Relapsed/Refractory Lymphoma With Renal Cancer: A Case Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e15-e17	2	1
106	Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. <i>BMC Cancer</i> , 2020 , 20, 1088	4.8	1
105	Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry. <i>Acta Haematologica</i> , 2021 , 144, 259-263	2.7	1
104	Critical concepts and management recommendations for cutaneous T-cell lymphoma: A consensus-based position paper from the Italian Group of Cutaneous Lymphoma. <i>Hematological Oncology</i> , 2021 , 39, 275-283	1.3	1
103	Sequential Double Bridging to Transplant with Diversified Anti- PD1 Monoclonal Antibodies Retreatment in Relapsed Hodgkin Lymphoma: A Case Report. <i>Journal of Cancer Science & Therapy</i> , 2018 , 10,	5	1
102	New Treatment Options in Advanced Stage Follicular Lymphoma. <i>HemaSphere</i> , 2018 , 2, e156	0.3	1

101	Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases. <i>Leukemia and Lymphoma</i> , 2021 , 1-4	1.9	1
100	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. <i>Blood Advances</i> , 2021 , 5, 4504-4514	7.8	1
99	Successful Pregnancies, Births, and Children Development Following Oocyte Cryostorage in Female Cancer Patients During 25 Years of Fertility Preservation.. <i>Cancers</i> , 2022 , 14,	6.6	1
98	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.. <i>Cancers</i> , 2021 , 14,	6.6	1
97	Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report. <i>European Journal of Haematology</i> , 2020 , 105, 505-507	3.8	0
96	Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report. <i>Clinical Case Reports (discontinued)</i> , 2020 , 8, 933-937	0.7	0
95	T-Cell Lymphoproliferative Disorders 2015 , 524-536		0
94	How do we define Hodgkin's disease? The authors' reply. <i>Journal of Clinical Pathology</i> , 2003 , 56, 159	3.9	0
93	Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab. <i>Journal of Translational Medicine</i> , 2021 , 19, 489	8.5	0
92	Clinical Response in Heavily Pretreated Mycosis Fungoides with Pembrolizumab: A Case Report. <i>Acta Haematologica</i> , 2021 , 1-3	2.7	0
91	Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2392-2399	1.9	0
90	Lymph node core needle biopsy in lymphoproliferative disorders-Authors' reply to Al-Abbadi and colleagues. <i>European Journal of Haematology</i> , 2021 , 107, 297-298	3.8	0
89	Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report. <i>Tumori</i> , 2021 , 107, NP105-NP107	1.7	0
88	Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3109-3118	1.9	0
87	A case report of the long treatment experience of a Sjögren syndrome responder patient: 16 years through all the systemic and innovative therapies. <i>Hematological Oncology</i> , 2019 , 37, 202-204	1.3	0
86	Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides). <i>JDDG - Journal of the German Society of Dermatology</i> , 2021 , 19, 99-102	1.2	0
85	Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1007-1009	1.9	0
84	Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e886-e894	2	0

83	BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience.. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022 , 1	4.9	o
82	Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.. <i>Frontiers in Oncology</i> , 2021 , 11, 789891	5.3	o
81	Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma - AuthorsReply. <i>Lancet Haematology,the</i> , 2017 , 4, e64-e66	14.6	
80	Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e321-e323	2	
79	Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 297-299	2	
78	RALE051: a novel established cell line of sporadic Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1252-1255	1.9	
77	Gastric MALT Lymphoma in a Sleeve Gastrectomy Specimen: Case Report and Literature Review. <i>Bariatric Surgical Patient Care</i> , 2018 , 13, 90-93	0.4	
76	PHASE 1B KEYNOTE-013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW-UP. <i>Hematological Oncology</i> , 2019 , 37, 296-298	1.3	
75	A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥5 Years) TREATMENT-NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019 , 37, 554-555	1.3	
74	SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS-1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019 , 37, 389-390	1.3	
73	COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA. <i>Hematological Oncology</i> , 2019 , 37, 399-400	1.3	
72	Reactive follicular lymphoid infiltrate: a new condition to exclude in patients with PET positivity inside the heart. <i>Journal of Nuclear Cardiology</i> , 2014 , 21, 402-5	2.1	
71	Past, present and future treatment strategies in peripheral T-cell lymphomas. <i>International Journal of Hematologic Oncology</i> , 2014 , 3, 299-311	1	
70	Primary ocular adnexal lymphomas: a retrospective study of 25 patients. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2076-8	1.9	
69	Peripheral T-cell lymphomas: in "real life" experience are we really improving?. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2337-8	1.9	
68	Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1791-3	1.9	
67	PHASE 1B STUDY OF CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMAS (NHL). <i>Hematological Oncology</i> , 2017 , 35, 53-53	1.3	
66	Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice. <i>Hematological Oncology</i> , 2017 , 35, 918-920	1.3	

- 65 Erythematous induration of the chest. *JDDG - Journal of the German Society of Dermatology*, **2015**, 13, 1291-3 1.2
- 64 Erythematöse Induration im Brustbereich. *JDDG - Journal of the German Society of Dermatology*, **2015**, 13, 1291-1293 1.2
- 63 PET in natural killer/T-cell lymphoma: the debate continues. *Lancet Haematology*, **2015**, 2, e50-1 14.6
- 62 Primary Mediastinal Large B-Cell Lymphoma **2014**, 282-285
- 61 Local versus systemic treatment for primary cutaneous B-cell lymphoma. *Clinical Lymphoma, Myeloma and Leukemia*, **2010**, 10 Suppl 2, S103-5 2
- 60 14 Recent progress in the treatment for T-cell malignancies. *European Journal of Cancer, Supplement*, **2010**, 8, 9 1.6
- 59 Lymphoproliferative Lung Disorders **2007**, 36, 307-322
- 58 The first International Workshop on Non-Hodgkin's Lymphoma: taking a close look at current issues and future developments. *Leukemia and Lymphoma*, **2003**, 44 Suppl 3, S1-4 1.9
- 57 Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?. *Leukemia Research*, **2003**, 27, 465-6 2.7
- 56 High-dose therapy followed by autologous bone marrow transplantation in previously untreated high grade non-Hodgkin's lymphoma: 10-year long-term results. *European Journal of Cancer*, **1995**, 31A, 2421-2 7.5
- 55 Anthracycline Containing Regimens in Intermediate Grade Lymphoma. *Leukemia and Lymphoma*, **1992**, 7, 22-24 1.9
- 54 Brentuximab vedotin in The Treatment of Relapsed/Refractory CD30+ Peripheral T-cell Lymphoma: a FIL Phase 2 Study.. *Hematological Oncology*, **2022**, 1.3
- 53 Report of a Phase II Study of Proteasome Inhibitor Bortezomib (Velcade) in Patients with Relapsed or Refractory T-Cell Lymphoma.. *Blood*, **2005**, 106, 4764-4764 2.2
- 52 A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.. *Blood*, **2006**, 108, 2478-2478 2.2
- 51 Standard of Care in T-Cell Lymphoma. *Essentials*, **2019**, 227-244 1
- 50 The Treatment of Hairy Cell Leukemia with a Focus on Long Lasting Responders to Cladribine: A Thirty-Year Experience from the Institute of Hematology of Bologna. *Blood*, **2019**, 134, 4005-4005 2.2
- 49 Finalization of autologous stem cell transplant in complex and multirelapsed follicular lymphoma. *Tumori*, **2020**, 106, NP5-NP8 1.7
- 48 Weekly Administration of 2-Chlorodeoxyadenosine in Patients With Hairy-Cell Leukemia: A New Treatment Schedule Effective and Safer in Preventing Infectious Complications. *Blood*, **1997**, 89, 1838-1839 2.2

- 47 Bendamustine in Combination with Rituximab for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients: An Italian Retrospective Multicentre Study. *Blood*, **2014**, 124, 1985-1985 2.2
- 46 Langerhans Cell Histiocytosis: A Single Institution Retrospective Analysis of Eleven Patients. *Blood*, **2014**, 124, 5458-5458 2.2
- 45 A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. *Blood*, **2014**, 124, 3300-3300 2.2
- 44 The Treatment of Primary Mediastinal Large B-Cell Lymphoma: A Two Decades Monocentric Experience on 98 Patients. *Blood*, **2014**, 124, 4440-4440 2.2
- 43 Efficacy and Safety of Biosimilar Epoetin Alpha in Patients with Chronic Lymphoproliferative Syndromes and Chemotherapy-Induced Anemia: An Observational, Retrospective, Monocentric Analysis. *Blood*, **2014**, 124, 5478-5478 2.2
- 42 Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients. *Blood*, **2015**, 126, 3937-3937^{2.2}
- 41 Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma. *Blood*, **2015**, 126, 2677-2677 2.2
- 40 18F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse. *Blood*, **2015**, 126, 5009-5009 2.2
- 39 Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma. *Blood*, **2016**, 128, 4161-4161 2.2
- 38 Lymphoma and Myeloma of the Sacrum **2017**, 227-235
- 37 Lung lymphoma **2008**, 183-195
- 36 ITF2357, a Novel Histone-Deacetylase Inhibitor, Is Effective against Peripheral T-Cell Lymphomas in Vivo. *Blood*, **2008**, 112, 4981-4981 2.2
- 35 Aberrant PDGFRA Signalling Is Sustained by An Autocrine Loop in Peripheral T-Cell Lymphoma Not Otherwise Specified. *Blood*, **2008**, 112, 5331-5331 2.2
- 34 Radioimmunotherapy Is Safe and Effective in Relapse after Stem Cell Transplantation for B- Cell Non Hodgkins Lymphoma, An Analysis of the International RIT-Network. *Blood*, **2008**, 112, 3064-3064 2.2
- 33 Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant.. *Blood*, **2009**, 114, 2699-2699 2.2
- 32 Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative Group on HCL). *Blood*, **2010**, 116, 1369-1369 2.2
- 31 PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA of the LUNG (BALT-LYMPHOMA): Results of a Retrospective Analysis on Behalf of IELSG. *Blood*, **2010**, 116, 1770-1770 2.2
- 30 The Small Molecule JAK1/JAK2 Inhibitor INCB16562 Shows Single Agent Activity and Strongly Synergizes with Bcl-2 Inhibitors in Lymphoma. *Blood*, **2011**, 118, 2731-2731 2.2

- 29 The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi. *Blood*, **2011**, 118, 2651-2651 2.2
- 28 Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi. *Blood*, **2011**, 118, 2636-2636 2.2
- 27 Effect of a combination of epigenetic agents on the malignant phenotype in models of T-cell lymphoma.. *Journal of Clinical Oncology*, **2012**, 30, e13569-e13569 2.2
- 26 Nucleoside Analogs in the Therapy of T-Cell Malignancies **2013**, 263-278
- 25 Collection of Hematopoietic Stem Cells After Previous Exposure to Itrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma.. *Blood*, **2012**, 120, 3019-3019 2.2
- 24 Fludarabine, Mitoxantrone and Rituximab (FMR) Regimen in Previously Untreated Patients with Indolent Non-Hodgkin Lymphoma: Efficacy, Safety and PET Data On 285 Patients.. *Blood*, **2012**, 120, 2736-2736 2.2
- 23 Genomic Instability and Activation Of The DNA Damage Response Pathway Is An Independent Predictor Of Poor Prognosis, Is Associated With MYC Expression and Is a Promising Target For Therapy In Diffuse Large B Cell Lymphoma. *Blood*, **2013**, 122, 3015-3015 2.2
- 22 Sequential R-CHOP and R-FM Chemotherapy Followed By Autologous Stem Cell Transplantation Results In High Rates Of Long Term Remission In Advanced Follicular Lymphoma. *Blood*, **2013**, 122, 5543-5543 2.2
- 21 Anaplastic Large Cell Lymphoma **2014**, 111-120
- 20 Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas. *Bone Marrow Transplantation*, **2021**, 56, 2295-2298 4.4
- 19 CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B-CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL. *Hematological Oncology*, **2019**, 37, 140-142 1.3
- 18 Approved Agents in the Relapsed or Refractory Setting, Excluding Brentuximab Vedotin **2021**, 287-304
- 17 Emerging Immunotherapy Approaches in Peripheral T-cell Lymphomas **2021**, 329-341
- 16 The Spectrum of Anaplastic Large-cell Lymphoma **2021**, 129-144
- 15 Epigenetics of T-cell Lymphoma **2021**, 27-45
- 14 Peripheral T-cell Lymphoma Not Otherwise Specified **2021**, 105-114
- 13 Standard Front-line Therapies **2021**, 269-286
- 12 Geographic Distribution of the Peripheral T-cell Lymphomas **2021**, 57-68

- 11 Human T-cell Lymphotropic Virus Type 1 Positive Adult T-cell Leukemia/Lymphoma **2021**, 145-157
- 10 Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?. *Current Hematologic Malignancy Reports*, **2021**, 16, 82-88 4-4
- 9 Molecular Classification of the Peripheral T-cell Lymphomas **2021**, 91-103
- 8 Angioimmunoblastic T-cell Lymphoma **2021**, 115-128
- 7 Hepatosplenic T-cell Lymphomas **2021**, 225-234
- 6 Innovative Chemotherapy-free Approaches for the Treatment of Peripheral T-Cell Lymphoma **2021**, 367-377
- 5 Cutaneous T-cell Lymphoma **2021**, 235-258
- 4 The Role of Autologous Stem-cell Transplantation in Peripheral T-cell Lymphomas **2021**, 305-318
- 3 Plaques und Tumoren unter der Therapie mit Mogamulizumab bei einer Patientin mit refraktärem Sjögren-Syndrom. *JDDG - Journal of the German Society of Dermatology*, **2018**, 16, 1263-1266 1.2
- 2 New Agents in Marginal Zone Lymphomas. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, S61-S62
- 1 Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series.. *Tumori*, **2022**, 3008916221090327 1.7